Back to Journals » Vascular Health and Risk Management » Volume 8

Avanafil for treatment of erectile dysfunction: review of its potential

Authors Burke RM, Evans JD

Received 2 May 2012

Accepted for publication 27 June 2012

Published 29 August 2012 Volume 2012:8 Pages 517—523

DOI https://doi.org/10.2147/VHRM.S26712

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Ryan M Burke,1 Jeffery D Evans2

1The University of Louisiana at Monroe College of Pharmacy, Monroe, LA, 2The University of Louisiana at Monroe College of Pharmacy, Shreveport, LA, USA

Abstract: Avanafil is a medication that was recently approved by the US Food and Drug Administration for the management of erectile dysfunction. Avanafil is a new phosphodiesterase type 5 inhibitor similar to sildenafil and tadalafil. Avanafil was studied in over 1300 patients during clinical trials, including patients with diabetes mellitus and those who had undergone radical prostatectomy, and was found to be more effective than placebo in all men who were randomized to the drug. The medication was studied with on-demand dosing that may occur after food and/or alcohol. Avanafil is dosed as 50 mg, 100 mg, or 200 mg tablets. Avanafil may differentiate itself from the other phosphodiesterase type 5 inhibitors with its quicker onset and higher specificity for phosphodiesterase type 5 versus other phosphodiesterase subtypes, but may lead to complications of therapy.

Keywords: avanafil, safety, efficacy, erectile dysfunction

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells

Wang F, Li H, Yan XG, Zhou ZW, Yi ZG, He ZX, Pan ST, Yang YX, Wang ZZ, Zhang X, Yang T, Qiu JX, Zhou SF

Drug Design, Development and Therapy 2015, 9:575-601

Published Date: 17 January 2015

Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance

El-Helou N, Al-Hajje A, Ajrouche R, Awada S, Rachidi S, Zein S, Salameh P

Vascular Health and Risk Management 2013, 9:81-88

Published Date: 1 March 2013

The potential benefit of stem cell therapy after stroke: an update

Banerjee S, Williamson DA, Habib N, Chataway J

Vascular Health and Risk Management 2012, 8:569-580

Published Date: 10 October 2012

Telmisartan and cardioprotection

Akhrass PR, McFarlane SI

Vascular Health and Risk Management 2011, 7:677-683

Published Date: 15 November 2011

Management of high-risk popliteal vascular blunt trauma: clinical experience with 62 cases

Ali Pourzand, Bassir A Fakhri, Ramin Azhough, et al

Vascular Health and Risk Management 2010, 6:613-618

Published Date: 14 July 2010